ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):: US04272N1028
LEI:
Country:: United States of America
Address:: 18 CAMPUS BLVD., NEWTOWN SQUARE
Website:: https://arrivent.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Icure Pharmaceutical Incorporation Develops transdermal patches for dementia/Parkinson's and offers cosmetic ODM/OBM services.	South Korea	175250
Idorsia Ltd Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.	Switzerland	IDIA
IGC Pharma, Inc. Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.	United States of America	IGC
IL DONG PHARMACEUTICAL CO., LTD. Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.	South Korea	249420
ILSUNG IS CO., LTD. Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.	South Korea	003120
ILYANG PHARMACEUTICAL CO.,LTD Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.	South Korea	007570
I-Mab A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.	United States of America	IMAB
ImageneBio, Inc. A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.	United States of America	IMA
IM Cannabis Corp. International producer of medical-grade cannabis for patients and providers in Israel and Germany.	United States of America	IMCC
Immatics N.V. Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.	United States of America	IMTX